Alto Neuroscience (NYSE:ANRO) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a sell rating in a report issued on Saturday morning.

ANRO has been the topic of a number of other reports. Jefferies Financial Group reissued a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Tuesday, March 17th. Wedbush raised their target price on shares of Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, March 17th. BTIG Research boosted their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $21.38 on Friday. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $25.17. The firm has a market capitalization of $683.12 million, a price-to-earnings ratio of -9.81 and a beta of 2.52. The business has a 50 day simple moving average of $18.47 and a 200 day simple moving average of $13.67. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.42.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. On average, equities research analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC lifted its holdings in Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares during the last quarter. Peapod Lane Capital LLC boosted its position in shares of Alto Neuroscience by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after purchasing an additional 3,106 shares in the last quarter. Torren Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter worth approximately $62,000. XTX Topco Ltd grew its stake in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the last quarter. Finally, Citizens Financial Group Inc. RI raised its holdings in shares of Alto Neuroscience by 19.0% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock worth $161,000 after purchasing an additional 6,394 shares in the last quarter.

Key Headlines Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Robert W. Baird raised its price target to $41, which can support upside sentiment and buying interest for growth/biotech investors. Robert W. Baird Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $41.00
• Positive Sentiment: Wedbush reiterated a constructive outlook for Alto and flagged potential strong price appreciation, supporting demand from momentum/coverage-driven buyers. Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating, another supportive analyst signal for investor confidence. Chardan Capital Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)
• Neutral Sentiment: Recent quarterly report (Mar 16) slightly beat EPS consensus, which provides some fundamental support versus the negative estimate revisions. Alto Neuroscience — Company Page
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions (Mar 18) to Alto’s near- and medium-term EPS: Q1 2026 to ($0.63) from ($0.59), Q2 2026 to ($0.67) from ($0.64), Q4 2026 to ($0.74) (earlier view higher), FY2026 to ($2.75) from ($2.51), and sharper cuts to FY2027–FY2029/FY2028 (e.g., FY2028 to ($4.11) from ($2.65); FY2029 to ($2.99) from ($1.54)). These more bearish earnings trajectories increase uncertainty on cash burn and timing to profitability, which likely explains much of the downward pressure on the stock today. HC Wainwright Lowers Earnings Estimates for Alto Neuroscience

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.